Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin’s lymphoma

Béranger Lueza, Anne Aupérin, Charlotte Rigaud, Thomas G. Gross, Marta Pillon, Rafael F. Delgado, Anne Uyttebroeck, G. A. Amos Burke, József Zsíros, Monika Csóka, Mathieu Simonin, Catherine Patte, Véronique Minard-Colin and Julia Bonastre ()
Additional contact information
Béranger Lueza: Gustave Roussy, Université Paris-Saclay
Anne Aupérin: Gustave Roussy, Université Paris-Saclay
Charlotte Rigaud: Gustave Roussy, Université Paris-Saclay
Thomas G. Gross: Children’s Hospital Colorado
Marta Pillon: University of Padova
Rafael F. Delgado: University of Valencia
Anne Uyttebroeck: University Hospitals Leuven
G. A. Amos Burke: Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital
József Zsíros: Princess Máxima Center for Pediatric Oncology
Monika Csóka: Semmelweis University
Mathieu Simonin: Armand Trousseau Hospital-APHP, Sorbonne University
Catherine Patte: Gustave Roussy, Université Paris-Saclay
Véronique Minard-Colin: Gustave Roussy, Université Paris-Saclay
Julia Bonastre: Gustave Roussy, Université Paris-Saclay

The European Journal of Health Economics, 2024, vol. 25, issue 2, No 10, 307-317

Abstract: Abstract Objectives The randomized controlled trial Inter-B-NHL ritux 2010 showed overall survival (OS) benefit and event-free survival (EFS) benefit with the addition of rituximab to standard Lymphomes Malins B (LMB) chemotherapy in children and adolescents with high-risk, mature B cell non-Hodgkin’s lymphoma. Our aim was to assess the cost-effectiveness of rituximab-chemotherapy versus chemotherapy alone in the French setting. Methods We used a decision-analytic semi-Markov model with four health states and 1-month cycles. Resource use was prospectively collected in the Inter-B-NHL ritux 2010 trial (NCT01516580). Transition probabilities were assessed from patient-level data from the trial (n = 328). In the base case analysis, direct medical costs from the French National Insurance Scheme and life-years (LYs) were computed in both arms over a 3-year time horizon. Incremental net monetary benefit and cost-effectiveness acceptability curve were computed through a probabilistic sensitivity analysis. Deterministic sensitivity analysis and several sensitivity analyses on key assumptions were also conducted, including one exploratory analysis with quality-adjusted life years as the health outcome. Results OS and EFS benefits shown in the Inter-B-NHL ritux 2010 trial translated into the model by rituximab-chemotherapy being the most effective and also the least expensive strategy over the chemotherapy strategy. The mean difference in LYs between arms was 0.13 [95% CI 0.02; 0.25], and the mean cost difference € − 3 710 [95% CI € − 17,877; € 10,525] in favor of rituximab-chemotherapy group. For a € 50,000 per LY willingness-to-pay threshold, the probability of the rituximab-chemotherapy strategy being cost-effective was 91.1%. All sensitivity analyses confirmed these findings. Conclusion Adding rituximab to LMB chemotherapy in children and adolescents with high-risk mature B-cell non-Hodgkin's lymphoma is highly cost-effective in France. Trial registration ClinicalTrials.gov identifier: NCT01516580.

Keywords: Economic evaluation; Semi-Markov model; High-risk B-NHL; Immunotherapy (search for similar items in EconPapers)
Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-023-01581-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:25:y:2024:i:2:d:10.1007_s10198-023-01581-y

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-023-01581-y

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().